IP
IndiaPulse

VENTIVE

Small Cap

Ventive Hospitality Limited

Consumer

Ventive Hospitality Limited operates in Hotels, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹625.95
-1.25 · -0.20%
Quote09 Jun, 10:02 am
Fundamentals08 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Mixed fundamentals, management trust is acceptable, price trend argues for patience, and recent execution is mixed.

Suggested next step
Research, do not rush
The four lenses are not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
FAIR VALUE
52

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Mixed Trust
63

low confidence · 0/0 claims checked

Technical
Neutral
43

Timing lens: price trend and sector relative strength.

Result consistency
stable
69

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Good · 67/100

Rev +12% YoY · PAT +72% YoY · +14% QoQ · operating leverage · margin compression

Filed 12 May 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹779 Cr+11.6%+13.6%
EBITDA₹385 Cr+9.4%+23.8%
Operating margin49.0%-100 bps+400 bps
PAT₹259 Cr+71.5%+85.0%
PAT margin33.3%+1162 bps+1284 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Issuer presentation review pending

Ventive Hospitality Limited operates in Hotels, within the Consumer sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Technical timing lens

Trend score and candlestick chart

43Neutral

SMA20 -10.6% / mo

Stock trend: 42
Sector RS: 45
Sector 3M: -0.7% vs Nifty +0.1%

Technical chart

VENTIVEweekly · 3Y-15.4%
Latest close ₹625.95 on 2026-06-09
Bar
-0.3%
RSI
44
MACD hist
3.61
52W pos
29%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹528₹608₹687₹766₹84652H52L2025-032025-062025-092025-122026-03Vol2025-012025-052025-102026-032026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Neutral

Trend is undirectional — long-term trend unclear. RSI 44.

  • SMA20 falling (~11.8% over last month) — short-term momentum negative.
  • RSI(14) at 44 — sideways, no extreme reading.
  • MACD above signal but histogram contracting — bullish momentum cooling.
  • 25% off 52W high · 15% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

52U-SCORE
Growth at Value

Fundamental score breakdown

FAIR VALUE
Valuation16/30
Growth19/25
Quality0/20
Balance Sheet7/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
52

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

52/100 · FAIR VALUE

Positive drivers

  • FCF yield is supportive at 4.3%.
  • Piotroski is strong at 8/9.
  • Fair-value margin of safety is positive at 56.0%.

Main drags

  • Promoter pledge is 41.1%.
  • Quality is weaker at 0/20; verify the latest quarterly trend.
  • Balance sheet is weaker at 7/15; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
34.0
PB
2.7
EV/EBITDA
12.1
ROE
8.3%
ROCE
10.8%
FCF Yield
4.3%
Debt/Equity
0.5
MoS
+56.0%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
52
Previous: 52
Verdict
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+56.0%
Previous: +56.1%

Score history

12 stored score snapshots. Latest stored move: +0 points.

08 Jun 2026
v4.2-nightly
52
52
52
52
52
52
52
52
52
52
52
52

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Trust Score
63Mixed Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Mixed Trust: Claim history is still being built. It ranks around the 38th percentile of the scored universe and 37th percentile within Consumer. Main check: promoter alignment is weak at 43/100.

Healthy Trust Lite: Promoter holding is 89%. Key concern: Promoters have pledged 41.1% of holding.

Computed 22 May 2026
trust-lite-v1
0 docs indexed · 0 concall links
Score band
Mixed Trust

Usable, but needs evidence. Treat guidance with a margin of safety.

Relative rank
38th percentile

overall median 67 · Consumer: 37th pctile, median 67 · Small: 43rd pctile, median 65

Evidence depth
Financial-only

0 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Mixed Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
43
weak · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
69
acceptable · quarterly consistency

Trust positives

  • Promoter holding is 89%.
  • FCF yield is positive at 4.3%.
  • 6/6 recent quarters had positive YoY revenue growth.
  • 4/5 recent quarters had positive YoY PAT growth.

Trust risks

  • Promoters have pledged 41.1% of holding.
  • OPM spread across recent quarters is 25%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹311.13
-101.2% MoS
DCF Fair PE
78.0
DCF Fair Value
₹1,421.94
+56.0% MoS
PEG
0.71

Fundamentals

Valuation

P/E
34.00
P/B
2.66
EV/EBITDA
12.12
Market Cap
14648.00Cr

Profitability

ROE
8.35%
ROCE
10.80%
ROA
4.70%
Dividend Y

Growth (CAGR)

Revenue 5Y
126.90%
EPS 5Y
73.90%
Revenue 3Y
9.00%
EPS 3Y
9.00%

Balance Sheet

Debt/Equity
0.47
Interest Coverage
4.78×
Altman Z
3.17
Book Value
236.00

Cash Flow

FCF Yield
4.34%
FCF Positive Y
2/5
OCF
950.00 Cr
EPS TTM
18.23

Shareholding

Promoter Hold
88.99%
Promoter Pledge
41.10%
Momentum 52W
28%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
Latest: 238-46.2% vs prev
0742.9Mar 2026: 743Mar 2025: 629Mar 2024: 495Mar 2023: 442Mar 2022: 238FY26FY25FY24FY23FY22

Net Profit

₹ Cr
No data

Return on Equity

%
No data
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.